Kushen flavonoids induce apoptosis in tumor cells by inhibition of NF-κB activation and multiple receptor tyrosine kinase activities

被引:38
作者
Han, Jun
Sun, Mingyu
Cui, Yumin
Wang, Tao
Zhang, Weihan
Guo, Mingchuan
Zhou, Yuan
Liu, Wei
Zhang, Meifang
Duan, Jifeng
Xiong, Sidong
Yao, Minghui
Yan, Xiaoqiang
机构
[1] Hutchison Medipharma Ltd, Dept Biol, Shanghai 201203, Peoples R China
[2] Hutchison Medipharma Ltd, Dept Pharmacol, Shanghai 201203, Peoples R China
[3] Fudan Univ, Shanghai Med Coll, Dept Immunol, Shanghai 200032, Peoples R China
关键词
Kushen; flavonoids; apoptosis; NF-kappa B activation; tyrosine kinase;
D O I
10.1002/ptr.2065
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In this report, the mechanism of the antitumor activities of Kushen flavonoids (KS-Fs) were explored. KS-Fs and kurarinone (Kur), a single flavonoid compound, were able to induce apoptosis of H460 and Eca-109 cells in vitro and H460 cells in vivo. The apoptosis inducing effect was enhanced in the presence of Taxol. In H460 xenograft mice treated with Kur, down-regulation of Bcl-2 and up-regulation of caspase 8 and caspase 3 in tumors were observed by immunohistochemical staining. In addition, KS-Fs and Kur were able to inhibit TNF alpha-induced NF-kappa B activation in 293 cells mediated by the decreased I kappa b alpha phosphorylation. Further the effects of KS-Fs and Kur on multiple receptor tyrosine kinase activities were explored. In cell-based assays, KS-Fs and Kur inhibited the EGF-induced EGF receptor phosphorylation in A431 cells and a constitutively activated Her-2 in MDA-MB-453s cells. In enzymatic assays, KS-Fs and Kur inhibited KDR, but not PDGF BR activities. In A431 xenograft mice treated with Kur, an inhibition of EGF receptor phosphorylation in tumors was observed. These results reveal a novel mechanism by which KS-Fs induces apoptosis in tumors by acting on multiple cellular targets including the inhibition of NF-kappa B activation and multiple receptor tyrosine kinase activities. Copyright (c) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:262 / 268
页数:7
相关论文
共 27 条
[1]   Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study [J].
Baas, P ;
Belderbos, JSA ;
Senan, S ;
Kwa, HB ;
van Bochove, A ;
van Tinteren, H ;
Burgers, JA ;
van Meerbeeck, J .
BRITISH JOURNAL OF CANCER, 2006, 94 (05) :625-630
[2]   Complementary and alternative therapies in the treatment of chronic hepatitis C: a systematic review [J].
Coon, JT ;
Ernst, E .
JOURNAL OF HEPATOLOGY, 2004, 40 (03) :491-500
[3]   TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer [J].
Herbst, RS ;
Prager, D ;
Hermann, R ;
Fehrenbacher, L ;
Johnson, BE ;
Sandler, A ;
Kris, MG ;
Tran, HT ;
Klein, P ;
Li, X ;
Ramies, D ;
Johnson, DH ;
Miller, VA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5892-5899
[4]  
HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134
[5]  
Hu Mei Jie, 2005, Chin J Dig Dis, V6, P68, DOI 10.1111/j.1443-9573.2005.00201.x
[6]   Death and anti-death: Tumour resistance to apoptosis [J].
Igney, FH ;
Krammer, PH .
NATURE REVIEWS CANCER, 2002, 2 (04) :277-288
[7]   Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec™) [J].
Ivan, D ;
Niveiro, M ;
Diwan, AH ;
Eton, O ;
Kim, KB ;
Lacey, C ;
Gonzalez, C ;
Prieto, VG .
JOURNAL OF CUTANEOUS PATHOLOGY, 2006, 33 (04) :280-285
[8]   Armepavine oxalate induces cell death on CCRF-CEM leukemia cell line through an apoptotic pathway [J].
Jow, GM ;
Wu, YC ;
Guh, JH ;
Teng, CM .
LIFE SCIENCES, 2004, 75 (05) :549-557
[9]   DOSE-INTENSE TAXOL - HIGH RESPONSE RATE IN PATIENTS WITH PLATINUM-RESISTANT RECURRENT OVARIAN-CANCER [J].
KOHN, EC ;
SAROSY, G ;
BICHER, A ;
LINK, C ;
CHRISTIAN, M ;
STEINBERG, SM ;
ROTHENBERG, M ;
ADAMO, DO ;
DAVIS, P ;
OGNIBENE, FP ;
CUNNION, RE ;
REED, E .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (01) :18-24
[10]  
Lee CT, 1996, CANCER RES, V56, P3038